ALK and non-small cell lung carcinoma: In a phase III trial comparing lorlatinib with crizotinib for ALK‐positive non‐small‐cell lung cancer (NSCLC) patients, lorlatinib demonstrated a significant extension in progression‐free survival (PFS).1